<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-146287" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pulmonary Hypertension Due to Lung Disease or Hypoxia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farishta</surname>
            <given-names>Mehdi</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sankari</surname>
            <given-names>Abdulghani</given-names>
          </name>
          <aff>Wayne State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mehdi Farishta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdulghani Sankari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-146287.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pulmonary hypertension (PH) is the elevated pressure in the pulmonary vascular system. Chronic obstructive pulmonary disease (COPD) and diffuse pulmonary lung disease (DPLD), including idiopathic pulmonary fibrosis (IPF) and combined pulmonary fibrosis and emphysema (CPFE), are the most common disease-causing chronic hypoxia and are associated with the highest incidence of pulmonary hypertension in this group. PH is classified according to the underlying pathophysiology of the disease. PH that develops due to advanced lung diseases and prolonged events of hypoxia is included in group 3. PH is a progressive condition with grave consequences if not recognized and optimized early in the disease. This activity reviews the evaluation for early recognition and optimization of PH and highlights the role of the interprofessional team in evaluating and managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify different causes of group 3 pulmonary hypertension.</p></list-item><list-item><p>Describe the pathophysiology of pulmonary hypertension due to hypoxia.</p></list-item><list-item><p>Review the diagnostic workup to identify the presence of pulmonary hypertension.</p></list-item><list-item><p>Identify the adverse events associated with uncontrolled pulmonary hypertension.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=146287&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=146287">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-146287.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pulmonary hypertension (PH) is a progressive disease that, if left untreated, can be life-threatening and lead to failure of the right ventricle. The 6th world symposium on pulmonary hypertension (WSPH), held in 2019, defined PH as mean pulmonary artery pressure (mPAP) &#x0003e; 20 mmHg.<xref ref-type="bibr" rid="article-146287.r1">[1]</xref> European society of cardiology and European respiratory society updated guidelines in 2022 and further classified PH as pre-capillary PH with pulmonary vascular resistance &#x0003e; 2 wood units and pulmonary wedge pressures less than or equal to 15 and post-capillary PH with pulmonary wedge pressures greater than 15 mmHg.<xref ref-type="bibr" rid="article-146287.r2">[2]</xref>&#x000a0;Furthermore, the World Health Organization (WHO) divided PH into five groups based on differences in pathophysiology and therapeutic options.<xref ref-type="bibr" rid="article-146287.r3">[3]</xref>&#x000a0;PH associated with respiratory system disorders due to chronic lung disease with or without hypoxemia is included in group 3. This article discusses etiology, epidemiology, clinical and physician manifestation, evaluation, and management.</p>
        <p>Other groups of&#x000a0;pulmonary hypertension include pulmonary arterial hypertension (group 1), PH due to left heart disease (group 2), PH due to chronic thromboembolic pulmonary hypertension (CTEPH) (group 4), and other miscellaneous disorders causing PH (group 5) will be discussed separately.</p>
      </sec>
      <sec id="article-146287.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Chronic obstructive pulmonary disease (COPD) and diffuse pulmonary lung disease (DPLD), including idiopathic pulmonary fibrosis (IPF) and combined pulmonary fibrosis and emphysema (CPFE), are the most common disease-causing chronic hypoxia and are associated with the highest incidence of pulmonary hypertension in this group.<xref ref-type="bibr" rid="article-146287.r4">[4]</xref>&#x000a0;Pulmonary&#x000a0;hypertension in this group varies with the severity of the disease. Most patients with COPD have mild to moderate PH, but a small group of patients with advanced COPD develops severe PH. The development of PH in this group of lung diseases is associated with a poor functional status, impaired quality of life, need for supplemental oxygen, and worse prognosis.</p>
        <p>Other conditions that PH may also develop are cystic fibrosis, chronic hypersensitivity pneumonitis, lung cancer, and other less common chronic lung diseases, including pulmonary Langerhans histiocytosis and lymphangioleiomyomatosis (LAM). The severity of PH is reported to be proportional to the extent of illness and parenchymal involvement.<xref ref-type="bibr" rid="article-146287.r5">[5]</xref>&#x000a0;A small percentage of PH is also reported in developmental lung disorders like bronchopulmonary dysplasia and congenital diaphragmatic hernia.<xref ref-type="bibr" rid="article-146287.r6">[6]</xref></p>
        <p>Other causes include pulmonary hypertension associated with hypoxia at high altitudes, which develops in people living over 2500 meters above sea level.<xref ref-type="bibr" rid="article-146287.r7">[7]</xref>&#x000a0;PH is reported more frequently in obesity hypoventilation syndrome (OHS) and overlap syndrome than in obstructive sleep apnea.<xref ref-type="bibr" rid="article-146287.r8">[8]</xref>&#x000a0;Due to associated nocturnal desaturation and worsening lung function, these patients with OHS usually present with more severe PH and poor prognosis.<xref ref-type="bibr" rid="article-146287.r9">[9]</xref></p>
      </sec>
      <sec id="article-146287.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Group 3 PH (associated with chronic lung diseases and hypoxia) has a higher incidence of PH than group 2 PH (due to left heart disease).<xref ref-type="bibr" rid="article-146287.r4">[4]</xref>&#x000a0;The prevalence of pulmonary hypertension in COPD is not known precisely, but it is estimated that approximately 10-30% of patients with mild to moderate COPD have PH.<xref ref-type="bibr" rid="article-146287.r10">[10]</xref>&#x000a0;The global initiative for chronic obstructive lung disease (GOLD) estimates that almost 90% of patients with COPD stage IV develop PH with mPAP &#x0003e; 20 mmHg.<xref ref-type="bibr" rid="article-146287.r11">[11]</xref>&#x000a0;PH is common in patients with IPF, and the prevalence of PH in IPF has been reported to be between 37-41%. The prevalence of PH in IPF may be higher as most of the reports come from patients evaluated for lung transplants with advanced IPF.<xref ref-type="bibr" rid="article-146287.r12">[12]</xref></p>
      </sec>
      <sec id="article-146287.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of PH group 3 is multifactorial and depends on the underlying disease processes. Pulmonary vasoconstriction in response to hypoxia plays a prominent role in the early phase of the disease process in both obstructive and restrictive lung disease. Prolonged hypoxemia impairs the release of endothelin-derived vasodilators like nitric oxide and prostaglandins. Also, it promotes the release of pulmonary vasoconstrictors like endothelin, increasing pulmonary vascular resistance (PVR).<xref ref-type="bibr" rid="article-146287.r13">[13]</xref>&#x000a0;</p>
        <p>In the late phase, remodeling of pulmonary microvessels with smooth muscle hyperplasia and constriction of intima leads to vascular lumen obliteration.<xref ref-type="bibr" rid="article-146287.r14">[14]</xref>&#x000a0;Other mechanical factors include vessel distortion due to the destruction of alveolar space in COPD and fibrosis in IPF elevates the pressure in the pulmonary vascular bed.<xref ref-type="bibr" rid="article-146287.r15">[15]</xref></p>
      </sec>
      <sec id="article-146287.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Symptoms of pulmonary hypertension significantly overlap with the underlying disease. For group 3 PH, it mimics the clinical manifestations of other groups except for clinical history of chronic lung disease and hypoxia during the day or nighttime. Although unexplained dyspnea is a ubiquitous presentation, in a recent survey of experts, it was not found to be very specific. Instead, the expert panel identified syncope, dizziness, and palpitations as highly predictive of PH.<xref ref-type="bibr" rid="article-146287.r16">[16]</xref>&#x000a0;</p>
        <p>Physical exam findings are not specific and cannot accurately predict the disease's progression. Poor oxygen saturation, jugular venous distension, peripheral edema, ascites, altered heart sounds (especially loud P2 or S2), right ventricular heave, and right-sided heart failure signs such as hepatomegaly are helpful but present later in the disease process.<xref ref-type="bibr" rid="article-146287.r17">[17]</xref><xref ref-type="bibr" rid="article-146287.r18">[18]</xref></p>
      </sec>
      <sec id="article-146287.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Due to the lack of sensitivity and specificity of physical examination, prompt screening and testing are required to establish the diagnosis. Pulmonary function tests (PFT) help to distinguish between restrictive and obstructive impairment. An out-of-proportion&#x000a0;decrease in diffusing capacity for carbon monoxide (DLCO) may predict the development of pulmonary hypertension and the need for further investigation. In general, a low DLCO (&#x0003c;40% of predicted) or rapid decline in DLCO (&#x02265; 15%), and a DLCO disproportionate to lung volumes (i.e., FVC/DLCO ratio &#x0003e; 1.6), is a trigger for a low threshold for suspicion for PH.<xref ref-type="bibr" rid="article-146287.r16">[16]</xref>&#x000a0;It is also associated with high PVR and is a predictor of increased mortality in patients with interstitial lung disease.<xref ref-type="bibr" rid="article-146287.r19">[19]</xref>&#x000a0;Therefore, a screening method was proposed for PH in patients with advanced IPF, which shows that using the ratio of FVC /DLCO when combined with SpO2 in linear regression formula has high sensitivity and negative predictive value to screen patients with mPAP &#x0003e; 21 mmHg.<xref ref-type="bibr" rid="article-146287.r20">[20]</xref></p>
        <p>Six-minute walk test (6MWT) and oxygen saturation on exertion also give insight into the underlying presence of PH. A worsening six-minute walk distance (6MWD) despite stable PFT, need for oxygen supplementation on exertion, and slow heart rate recovery in one minute can predict underlying PH.<xref ref-type="bibr" rid="article-146287.r21">[21]</xref><xref ref-type="bibr" rid="article-146287.r22">[22]</xref>&#x000a0;However, there is no specific threshold identified to date for 6MWD or desaturation to predict the presence of PH.</p>
        <p>When there is high clinical suspicion of pulmonary hypertension, the consensus from experts recommends obtaining echocardiography and Brain natriuretic peptide (BNP) or NT-proBNP. Transthoracic echocardiography (TTE) is considered the most useful non-invasive screening test for PH. Right ventricular systolic pressure (RVSP) can be estimated using the peak tricuspid regurgitation velocity, and systolic pulmonary artery pressures (sPAP) can be predicted using inferior vena cava (IVC) dilatation and collapsibility as a surrogate marker for right atrial pressures. TTE also helps to distinguish between pre-capillary and post-capillary hypertension by measuring left-sided parameters such as left atrial dilation and elevated diastolic filling pressures. Several studies, however, have shown that estimation of pressure through TTE can significantly overestimate the RVSP in chronic lung disease and lead to overdiagnosis of group 3 PH.<xref ref-type="bibr" rid="article-146287.r23">[23]</xref><xref ref-type="bibr" rid="article-146287.r5">[5]</xref>&#x000a0;A study looked into adding other factors, including right ventricular outflow tract (RVOT) diameter and tricuspid annular plane systolic excursion (TAPSE) with RVSP, showed improved sensitivity and negative predictive value to predict PH in patients with advanced lung disease.<xref ref-type="bibr" rid="article-146287.r24">[24]</xref></p>
        <p>Serum biomarkers such as BNP or N terminal-pro-BNP concentrations are useful screening tools for assessing patients with ILD-related-PH. Serum BNP levels are an independent prognostic marker used for risk evaluation. BNP, however, loses sensitivity when PH is cofounded by left heart disease.<xref ref-type="bibr" rid="article-146287.r25">[25]</xref><xref ref-type="bibr" rid="article-146287.r26">[26]</xref></p>
        <p>Pulmonary hypertension can be multifactorial and present as a spectrum of diseases due to the right and left heart disease. Right heart catheterization (RHC) is the gold standard for confirming the diagnosis of PH due to&#x000a0;chronic lung disease&#x000a0;and hypoxia. RHC can be valuable in distinguishing between pre- and post-capillary disease or the presence of combined pre-capillary and post-capillary disease. RHC is recommended for patients with exaggerated symptoms not explained by the extent of the underlying condition, patients undergoing evaluation for treatment with vasodilators, and patients being considered for a lung transplant. However, a low threshold for RHC is appropriate to confirm a PH diagnosis, particularly in those with high clinical suspicion of PH and right ventricular abnormalities on echocardiography (including dilation or enlargement and a low tricuspid annular plane systolic excursion) and in those with autoimmune ILD.</p>
        <p>In addition to PFT and 6MWD, other useful testing modalities are chest Computed Tomography (CT) scans which can be very useful to evaluate ILD stability or progression when symptoms are disproportionate to the severity of the underlying ILD.</p>
        <p>CT scan of the chest is commonly obtained in patients with COPD and ILD to measure the disease's extent and screen for lung cancer. There is no significant correlation between the extent of parenchymal changes seen on high-resolution CT imaging and the presence and degree of PH.<xref ref-type="bibr" rid="article-146287.r27">[27]</xref></p>
        <p>The ratio of the main pulmonary artery to ascending aorta greater than 0.9 in IPF predicted PH and worse outcomes.<xref ref-type="bibr" rid="article-146287.r28">[28]</xref><xref ref-type="bibr" rid="article-146287.r29">[29]</xref></p>
      </sec>
      <sec id="article-146287.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The goal of the management of PH in group 3 is to optimize the underlying disease and improve the functional status. This includes guideline-directed therapy using appropriate bronchodilators in obstructive lung disease, antifibrotics in patients with fibrotic lung disease, and immunosuppressive agents in connective tissue disease-induced ILD to slow disease progression.</p>
        <p>Patients with obesity hypoventilation syndrome (OHS) should be encouraged to use noninvasive mechanical ventilation (NIV).<xref ref-type="bibr" rid="article-146287.r30">[30]</xref> Long-term use of NIV in OHS has been shown to improve pulmonary hemodynamics.<xref ref-type="bibr" rid="article-146287.r31">[31]</xref></p>
        <p>In patients with advanced disease with hypoxemia, long-term oxygen therapy (LTOT) in patients with COPD has shown a decrease in the progression of PH when used for &#x0003e;15 hours and improvement in PAP when used for &#x0003e;18 hours.<xref ref-type="bibr" rid="article-146287.r32">[32]</xref><xref ref-type="bibr" rid="article-146287.r33">[33]</xref>&#x000a0;However, there is no direct evidence to support that the use of LTOT in pulmonary fibrosis slows PH progression. Still, supplementary oxygen should be prescribed to avoid prolonged episodes of hypoxia which can potentially further worsen pulmonary hypertension.</p>
        <p>Systemic vasodilators have been associated with concerns regarding the theoretical risk of worsening gas exchange due to hypoxic vasoconstriction and subsequent ventilation-perfusion mismatch.<xref ref-type="bibr" rid="article-146287.r34">[34]</xref>&#x000a0;Although this has not been observed in the multiple trials conducted to investigate the potential use of vasodilators in patients with ILD.<xref ref-type="bibr" rid="article-146287.r4">[4]</xref>&#x000a0;Trials with endothelin receptor antagonists, including Bosentan, Macitentan, and Ambrisentan, have shown no benefit but may be harmful.<xref ref-type="bibr" rid="article-146287.r35">[35]</xref><xref ref-type="bibr" rid="article-146287.r36">[36]</xref><xref ref-type="bibr" rid="article-146287.r37">[37]</xref>&#x000a0;A trial with Riociguat, a soluble guanylate cyclase stimulator, was stopped early due to increased adverse events and mortality.<xref ref-type="bibr" rid="article-146287.r38">[38]</xref>&#x000a0;Phosphodiesterase-type 5 inhibitors (PDE5i) have been studied in multiple trials in patients with chronic lung disease with no significant improvement in 6MWD or quality of life.<xref ref-type="bibr" rid="article-146287.r39">[39]</xref><xref ref-type="bibr" rid="article-146287.r40">[40]</xref></p>
        <p>The most recent use of inhaled treprostinil in the INCREASE trial showed an improved six-minute walk distance compared to patients who received a placebo. This supports the idea that inhaled vasodilators may cause less ventilation-perfusion mismatch than systemic use of vasodilators.<xref ref-type="bibr" rid="article-146287.r41">[41]</xref></p>
        <p>While most vasodilator therapies are not effective and may be harmful, inhaled treprostinil is approved in group 3 PH. Based on the INCREASE trial, the US FDA approved inhaled treprostinil as the first and only treatment for group 3 PH associated with ILD. When supportive therapy and inhaled vasodilator therapy fail to control the disease progression, systemic vasodilators can be cautiously trialed on a case-by-case basis in tertiary&#x000a0;pulmonary hypertension centers.&#x000a0;</p>
        <p>Patients with advanced lung disease should be referred to centers with expertise in advanced lung disease and pulmonary hypertension for early evaluation of the lung transplant.<xref ref-type="bibr" rid="article-146287.r4">[4]</xref>&#x000a0;The international society for heart and lung transplant Guidelines recommends that patients with IPF should be referred to the transplant center when FVC &#x0003c; 80% and DLCO &#x0003c; 40% predicted or progressive decline in FVC and DLCO of 10% and 15% of predicted, respectively. Similarly, patients with COPD should be referred with FEV1&#x0003c; 25% of predicted and a BODE score &#x0003e;5.<xref ref-type="bibr" rid="article-146287.r42">[42]</xref></p>
      </sec>
      <sec id="article-146287.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Suspected patients with group 3 PH should undergo diagnostic workup to exclude other causes of PH, including valvular heart disease and decompensated left heart disease (group 2), chronic thromboembolism, venous thromboembolism (group 4), and infection. It is essential to distinguish and understand the driving etiology of PH as it changes the management options and prognosis.</p>
        <p>Group 3 PH in patients with lung disease can co-exist with group 1 PH, particularly in connective tissue &#x02013; ILD cases. PH in these patients can be a continuum, contributed by hypoxia and other disease factors. These patients should be referred to a center with PH expertise for individualized management. Patients with group 3 lung disease, particularly ILD patients, can have simultaneous pre-capillary and post-capillary PH due to the prevalence of coronary artery disease.<xref ref-type="bibr" rid="article-146287.r43">[43]</xref></p>
      </sec>
      <sec id="article-146287.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Pulmonary hypertension in COPD is usually mild to moderate in severity, with mPAP between 20 and 35 mmHg with the progression of pulmonary artery pressures at approximately &#x0003c; 0.5 mmHg/year.<xref ref-type="bibr" rid="article-146287.r44">[44]</xref>&#x000a0;A small subgroup of patients (5%) with advanced COPD exhibits a severe progression of PH with pulmonary artery pressures (mPAP &#x0003e; 35 mmHg) with poor circulatory reserves more than the ventilatory reserves expected for the respiratory impairment seen in the pulmonary function test. PH in COPD is a strong predictor of survival and is associated with poor outcomes and high mortality.<xref ref-type="bibr" rid="article-146287.r4">[4]</xref><xref ref-type="bibr" rid="article-146287.r45">[45]</xref></p>
        <p>Pulmonary hypertension associated with IPF is recognized to have a worse prognosis and poor quality of life.<xref ref-type="bibr" rid="article-146287.r21">[21]</xref>&#x000a0;Patients with IPF were found to have higher 1-year mortality compared to a cohort of lung transplant patients without PH. Similarly, patients with combined pulmonary fibrosis and emphysema develop severe PH and fear a worse prognosis than patients with IPF without emphysema.<xref ref-type="bibr" rid="article-146287.r46">[46]</xref></p>
      </sec>
      <sec id="article-146287.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Elevated pressures in the pulmonary artery secondary to hypoxia from untreated and progressively worsening chronic lung disease increase right ventricular afterload. Due to the slow progression of pulmonary vascular resistance (PVR)in the setting of group 3 PH, RV adapts and hypertrophy to compensate for the high afterload. This subsequently causes RV diastolic dysfunction and paves the way to right ventricular and pulmonary artery (RV-PA) uncoupling. In one study, RV dysfunction was seen as worse in group 3 PH compared to patients in group 1 PH despite less severe PVR. Worse outcomes were also observed in the male gender. [46] In addition, lung hyperinflation and an increase in intrapleural pressures decrease the preload and venous return to RV. Under the persistently high afterload, RV eventually fails with reduced systolic function, and cor pulmonale ensues.<xref ref-type="bibr" rid="article-146287.r47">[47]</xref></p>
      </sec>
      <sec id="article-146287.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with group 3 PH should be educated on adherence to therapy for the underlying disease resulting in pulmonary hypertension. Patients with advanced restrictive and obstructive lung disease requiring oxygen supplementation should be counseled on the continued use of oxygen therapy to avoid periods of prolonged hypoxia. Good compliance with inhalers for patients with COPD and consideration for anti-fibrotic treatment in pulmonary fibrosis may prove to be vital to slow PH progression.</p>
        <p>Close follow-up with pulmonologists and early referral to PH experts are crucial to detect the early disease progression and initiation of therapy. Patients should be screened and referred for evaluation of lung transplants.</p>
      </sec>
      <sec id="article-146287.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Group 3 PH onset is silent due to signs and symptoms similar to the underlying lung disease and long-standing hypoxia. Progression of pulmonary hypertension can affect the patient&#x02019;s quality of life and worsen mortality. Thus, it is imperative to recognize the development of PH in the early stage of the disease, which may improve long-term patient outcomes and survival.</p>
        <p>Managing pulmonary hypertension requires an interprofessional team of clinicians, including a primary physician, pulmonologist, PH expert, specialty pharmacist, radiologist, and echocardiography expert. Patients with PH require close follow-up with regular lab work, echocardiography, 6MWD, and oxygen saturation on exertion to track the progression of the disease. Shared decision-making between the multiple specialties is required to plan and advance the treatment. Group 3 PH can overlap with group 1 (PAH) and group 2 PH (left heart disease) and requires referral to centers with expertise in treating PH with ongoing clinical trials.<xref ref-type="bibr" rid="article-146287.r48">[48]</xref>&#x000a0;[Class IC recommendation]&#x000a0;Due to the progressive nature of some lung diseases causing PH, patients may need evaluation and referral to a center for a lung transplant.</p>
      </sec>
      <sec id="article-146287.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=146287&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=146287">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/pulmonary-hypertension-due-to-lung-disease-or-hypoxia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=146287">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/146287/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=146287">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-146287.s15">
        <title>References</title>
        <ref id="article-146287.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Montani</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Celermajer</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Denton</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Gatzoulis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Krowka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Souza</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30545968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Badagliacca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>RMF</given-names>
              </name>
              <name>
                <surname>Brida</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carlsen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJS</given-names>
              </name>
              <name>
                <surname>Escribano-Subias</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Giannakoulas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kiely</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Meszaros</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nagavci</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Pepke-Zaba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Quint</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>R&#x000e5;degran</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Tonia</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Toshner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vachiery</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Vonk Noordegraaf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delcroix</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenkranz</surname>
                <given-names>S</given-names>
              </name>
              <collab>ESC/ERS Scientific Document Group</collab>
            </person-group>
            <article-title>2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.</article-title>
            <source>Eur Heart J</source>
            <year>2022</year>
            <month>Oct</month>
            <day>11</day>
            <volume>43</volume>
            <issue>38</issue>
            <fpage>3618</fpage>
            <page-range>3618-3731</page-range>
            <pub-id pub-id-type="pmid">36017548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC)</collab>
              <collab>European Respiratory Society (ERS)</collab>
              <collab>International Society of Heart and Lung Transplantation (ISHLT)</collab>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vachiery</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Barbera</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Beghetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Corris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gaine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Gomez-Sanchez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Jondeau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Klepetko</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Opitz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zellweger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the diagnosis and treatment of pulmonary hypertension.</article-title>
            <source>Eur Respir J</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>1219</fpage>
            <page-range>1219-63</page-range>
            <pub-id pub-id-type="pmid">19749199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seeger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Adir</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Barber&#x000e0;</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Champion</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Coghlan</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>De Marco</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Semigran</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Vachi&#x000e9;ry</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension in chronic lung diseases.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Dec</month>
            <day>24</day>
            <volume>62</volume>
            <issue>25 Suppl</issue>
            <fpage>D109</fpage>
            <page-range>D109-16</page-range>
            <pub-id pub-id-type="pmid">24355635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Barbera</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Gaine</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Harari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Olschewski</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Pepke-Zaba</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Provencher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weissmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension in chronic lung disease and hypoxia.</article-title>
            <source>Eur Respir J</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>53</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30545980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varghese</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Tillman</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension is an important co-morbidity in developmental lung diseases of infancy: Bronchopulmonary dysplasia and congenital diaphragmatic hernia.</article-title>
            <source>Pediatr Pulmonol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>670</fpage>
            <page-range>670-677</page-range>
            <pub-id pub-id-type="pmid">33561308</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirrakhimov</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Strohl</surname>
                <given-names>KP</given-names>
              </name>
            </person-group>
            <article-title>High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management.</article-title>
            <source>Open Cardiovasc Med J</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>19</fpage>
            <page-range>19-27</page-range>
            <pub-id pub-id-type="pmid">27014374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castro-A&#x000f1;&#x000f3;n</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Golpe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-de-Llano</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez Gonz&#x000e1;lez</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Escalona Velasquez</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez Fern&#x000e1;ndez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Testa Fern&#x000e1;ndez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez Quintela</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Haemodynamic effects of non-invasive ventilation in patients with obesity-hypoventilation syndrome.</article-title>
            <source>Respirology</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>8</issue>
            <fpage>1269</fpage>
            <page-range>1269-74</page-range>
            <pub-id pub-id-type="pmid">22897169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagaoka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kikuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Finger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Inami</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Soejima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Satoh</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Nocturnal Hypoxemia, But Not Sleep Apnea, Is Associated With a Poor Prognosis in Patients With Pulmonary Arterial Hypertension.</article-title>
            <source>Circ J</source>
            <year>2018</year>
            <month>Nov</month>
            <day>24</day>
            <volume>82</volume>
            <issue>12</issue>
            <fpage>3076</fpage>
            <page-range>3076-3081</page-range>
            <pub-id pub-id-type="pmid">30333436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elwing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Panos</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension associated with COPD.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2008</year>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-70</page-range>
            <pub-id pub-id-type="pmid">18488429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2022</year>
            <volume>17</volume>
            <fpage>1365</fpage>
            <page-range>1365-1379</page-range>
            <pub-id pub-id-type="pmid">35711174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Shlobin</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Leslie</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis.</article-title>
            <source>Respiration</source>
            <year>2008</year>
            <volume>76</volume>
            <issue>3</issue>
            <fpage>288</fpage>
            <page-range>288-94</page-range>
            <pub-id pub-id-type="pmid">18216461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lumb</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Slinger</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications.</article-title>
            <source>Anesthesiology</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>932</fpage>
            <page-range>932-46</page-range>
            <pub-id pub-id-type="pmid">25587641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Christou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.</article-title>
            <source>Am J Physiol Heart Circ Physiol</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>322</volume>
            <issue>5</issue>
            <fpage>H702</fpage>
            <page-range>H702-H724</page-range>
            <pub-id pub-id-type="pmid">35213243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kolb</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Hassoun</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Right ventricular dysfunction in chronic lung disease.</article-title>
            <source>Cardiol Clin</source>
            <year>2012</year>
            <month>May</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>243</fpage>
            <page-range>243-56</page-range>
            <pub-id pub-id-type="pmid">22548815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahaghi</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Kolaitis</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Adegunsoye</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Andrade</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Preston</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Safdar</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Saggar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scholand</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Shlobin</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Zisman</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study.</article-title>
            <source>Chest</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>162</volume>
            <issue>1</issue>
            <fpage>145</fpage>
            <page-range>145-155</page-range>
            <pub-id pub-id-type="pmid">35176276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shellenberger</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Imtiaz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chellappa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gundapanneni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Scheidel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Handa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Physical Examination for the Detection of Pulmonary Hypertension: A Systematic Review.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>e18020</fpage>
            <pub-id pub-id-type="pmid">34692270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braganza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Solverson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Janovcik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Varughese</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Thakrar</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Hirani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Helmersen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weatherald</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A Prospective Evaluation of the Diagnostic&#x000a0;Accuracy of the Physical Examination for Pulmonary Hypertension.</article-title>
            <source>Chest</source>
            <year>2019</year>
            <month>May</month>
            <volume>155</volume>
            <issue>5</issue>
            <fpage>982</fpage>
            <page-range>982-990</page-range>
            <pub-id pub-id-type="pmid">30826305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rose</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Archer</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Pritzker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Misialek</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Thenappan</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Survival in pulmonary hypertension due to chronic lung disease: Influence of low diffusion capacity of the lungs for carbon monoxide.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-155</page-range>
            <pub-id pub-id-type="pmid">30391191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zisman</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Karlamangla</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Shlobin</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Saggar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Belperio</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ardehali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis.</article-title>
            <source>Chest</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>133</volume>
            <issue>3</issue>
            <fpage>640</fpage>
            <page-range>640-5</page-range>
            <pub-id pub-id-type="pmid">18198245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lettieri</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shorr</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis.</article-title>
            <source>Chest</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>746</fpage>
            <page-range>746-52</page-range>
            <pub-id pub-id-type="pmid">16537877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swigris</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Shlobin</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Ahmad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis.</article-title>
            <source>Respirology</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>439</fpage>
            <page-range>439-45</page-range>
            <pub-id pub-id-type="pmid">20946337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arcasoy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Sutton</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Zisman</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Pochettino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kotloff</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2003</year>
            <month>Mar</month>
            <day>01</day>
            <volume>167</volume>
            <issue>5</issue>
            <fpage>735</fpage>
            <page-range>735-40</page-range>
            <pub-id pub-id-type="pmid">12480614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nowak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hudzik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jastrz&#x00229;bski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Niedziela</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Rozentryt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wojarski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ochman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karolak</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>&#x0017b;egle&#x00144;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gierlotka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x00105;sior</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension in advanced lung diseases: Echocardiography as an important part of patient evaluation for lung transplantation.</article-title>
            <source>Clin Respir J</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>930</fpage>
            <page-range>930-938</page-range>
            <pub-id pub-id-type="pmid">28052583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leuchte</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Neurohr</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baumgartner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Holzapfel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giehrl</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vogeser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2004</year>
            <month>Aug</month>
            <day>15</day>
            <volume>170</volume>
            <issue>4</issue>
            <fpage>360</fpage>
            <page-range>360-5</page-range>
            <pub-id pub-id-type="pmid">15087298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis.</article-title>
            <source>Respir Med</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>103</volume>
            <issue>2</issue>
            <fpage>180</fpage>
            <page-range>180-6</page-range>
            <pub-id pub-id-type="pmid">19097877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zisman</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Karlamangla</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Belperio</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Saggar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ardehali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goldin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis.</article-title>
            <source>Chest</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>773</fpage>
            <page-range>773-9</page-range>
            <pub-id pub-id-type="pmid">17573485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Vishin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Wille</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Dransfield</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>CT scan-measured pulmonary artery to aorta ratio and echocardiography for detecting pulmonary hypertension in severe COPD.</article-title>
            <source>Chest</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>145</volume>
            <issue>4</issue>
            <fpage>824</fpage>
            <page-range>824-832</page-range>
            <pub-id pub-id-type="pmid">24114440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kondoh</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kataoka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Furukawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johkoh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hasegawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis.</article-title>
            <source>Respirology</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>7</issue>
            <fpage>1393</fpage>
            <page-range>1393-1399</page-range>
            <pub-id pub-id-type="pmid">28488784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sankari</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Noninvasive Ventilation</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>11</day>
            <pub-id pub-id-type="pmid">35201716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000f6;nhofer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barchfeld</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hler</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Long term effects of non-invasive mechanical ventilation on pulmonary haemodynamics in patients with chronic respiratory failure.</article-title>
            <source>Thorax</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>524</fpage>
            <page-range>524-8</page-range>
            <pub-id pub-id-type="pmid">11413350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shujaat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Minkin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eden</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension and chronic cor pulmonale in COPD.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2007</year>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-82</page-range>
            <pub-id pub-id-type="pmid">18229565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weitzenblum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sautegeau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ehrhart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mammosser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease.</article-title>
            <source>Am Rev Respir Dis</source>
            <year>1985</year>
            <month>Apr</month>
            <volume>131</volume>
            <issue>4</issue>
            <fpage>493</fpage>
            <page-range>493-8</page-range>
            <pub-id pub-id-type="pmid">3922267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barber&#x000e0;</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Peinado</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension in chronic obstructive pulmonary disease.</article-title>
            <source>Eur Respir J</source>
            <year>2003</year>
            <month>May</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>892</fpage>
            <page-range>892-905</page-range>
            <pub-id pub-id-type="pmid">12765440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kawut</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Flaherty</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
              <name>
                <surname>Collard</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Costabel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Andrade</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Montgomery</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Chien</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>O'Riordan</surname>
                <given-names>TG</given-names>
              </name>
              <collab>ARTEMIS-IPF Investigators*</collab>
            </person-group>
            <article-title>Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.</article-title>
            <source>Ann Intern Med</source>
            <year>2013</year>
            <month>May</month>
            <day>07</day>
            <volume>158</volume>
            <issue>9</issue>
            <fpage>641</fpage>
            <page-range>641-9</page-range>
            <pub-id pub-id-type="pmid">23648946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raghu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Million-Rousseau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Morganti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perchenet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>J</given-names>
              </name>
              <collab>MUSIC Study Group</collab>
            </person-group>
            <article-title>Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.</article-title>
            <source>Eur Respir J</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>1622</fpage>
            <page-range>1622-32</page-range>
            <pub-id pub-id-type="pmid">23682110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stolz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rasch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Linka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Valentino</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brutsche</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tamm</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A randomised, controlled trial of bosentan in severe COPD.</article-title>
            <source>Eur Respir J</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>619</fpage>
            <page-range>619-28</page-range>
            <pub-id pub-id-type="pmid">18448495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Behr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Collard</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Cottin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Corte</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Keogh</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Leuchte</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mogulkoc</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wuyts</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Boateng</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>AU</given-names>
              </name>
            </person-group>
            <article-title>Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.</article-title>
            <source>Lancet Respir Med</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>9</issue>
            <fpage>780</fpage>
            <page-range>780-790</page-range>
            <pub-id pub-id-type="pmid">31416769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis.</article-title>
            <source>Sci Rep</source>
            <year>2021</year>
            <month>Sep</month>
            <day>08</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>17824</fpage>
            <pub-id pub-id-type="pmid">34497295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goudie</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lipworth</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Hopkinson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Struthers</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial.</article-title>
            <source>Lancet Respir Med</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>293</fpage>
            <page-range>293-300</page-range>
            <pub-id pub-id-type="pmid">24717626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waxman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Restrepo-Jaramillo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thenappan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ravichandran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bajwa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Argula</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rollins</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tapson</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nathan</surname>
                <given-names>SD</given-names>
              </name>
            </person-group>
            <article-title>Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Jan</month>
            <day>28</day>
            <volume>384</volume>
            <issue>4</issue>
            <fpage>325</fpage>
            <page-range>325-334</page-range>
            <pub-id pub-id-type="pmid">33440084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leard</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Holm</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Valapour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glanville</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Attawar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aversa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Campos</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Christon</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Cypel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dellgren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hartwig</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Kapnadak</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Kolaitis</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Kotloff</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Shlobin</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Sol&#x000e9;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wijsenbeek</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Willemse</surname>
                <given-names>BWM</given-names>
              </name>
              <name>
                <surname>Arcasoy</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>11</issue>
            <fpage>1349</fpage>
            <page-range>1349-1379</page-range>
            <pub-id pub-id-type="pmid">34419372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reed</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Eberlein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Girgis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iacono</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Netzer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scharf</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Coronary artery disease is under-diagnosed and under-treated in advanced lung disease.</article-title>
            <source>Am J Med</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>125</volume>
            <issue>12</issue>
            <fpage>1228.e13</fpage>
            <page-range>1228.e13-1228.e22</page-range>
            <pub-id pub-id-type="pmid">22959785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chaouat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Naeije</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Weitzenblum</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pulmonary hypertension in COPD.</article-title>
            <source>Eur Respir J</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>1371</fpage>
            <page-range>1371-85</page-range>
            <pub-id pub-id-type="pmid">18978137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanco</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tura-Ceide</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Peinado</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Barber&#x000e0;</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Updated Perspectives on Pulmonary Hypertension in COPD.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2020</year>
            <volume>15</volume>
            <fpage>1315</fpage>
            <page-range>1315-1324</page-range>
            <pub-id pub-id-type="pmid">32606641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mej&#x000ed;a</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carrillo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rojas-Serrano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Estrada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barrientos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gaxiola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Selman</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension.</article-title>
            <source>Chest</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>136</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <page-range>10-15</page-range>
            <pub-id pub-id-type="pmid">19225068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dorfm&#x000fc;ller</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shlobin</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Ventetuolo</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Group 3 Pulmonary Hypertension: From Bench to Bedside.</article-title>
            <source>Circ Res</source>
            <year>2022</year>
            <month>Apr</month>
            <day>29</day>
            <volume>130</volume>
            <issue>9</issue>
            <fpage>1404</fpage>
            <page-range>1404-1422</page-range>
            <pub-id pub-id-type="pmid">35482836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-146287.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Humbert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vachiery</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simonneau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vonk Noordegraaf</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beghetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghofrani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gomez Sanchez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hansmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Klepetko</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lancellotti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matucci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonagh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pierard</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Trindade</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Zompatori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoeper</surname>
                <given-names>M</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).</article-title>
            <source>Eur Heart J</source>
            <year>2016</year>
            <month>Jan</month>
            <day>01</day>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-119</page-range>
            <pub-id pub-id-type="pmid">26320113</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
